Ketorolac for Cachexia in Pancreatic Cancer
(KetoROCX Trial)

Recruiting in Palo Alto (17 mi)

Overseen byAndrew Hendifar, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Andrew Hendifar, MD

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing if ketorolac, a drug that reduces pain and swelling, can help pancreatic cancer patients maintain or gain weight and feel better overall. Ketorolac has been used effectively for pain management in various surgical procedures, including in children and infants.

Eligibility Criteria

This trial is for adults with advanced pancreatic cancer and cachexia, which means they've lost a lot of weight due to illness. They need good kidney function, internet access for a Smart Scale, and an ECOG performance status ≤2 or Karnofsky >50%. Pregnant women or those at risk of bleeding can't join.

Inclusion Criteria

I can take care of myself but might not be able to do heavy physical work.

I have advanced pancreatic cancer that has not responded to treatment and am referred to Cedars-Sinai.

My kidney function, measured by creatinine levels or filtration rate, is within the required range.

+2 more

Exclusion Criteria

I am at high risk of bleeding or bruise easily.

Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator

I am not taking any other NSAIDs while participating in this study.

+5 more

Participant Groups

The study tests if ketorolac, an anti-inflammatory drug, is safe and effective in stabilizing or increasing the weight and improving quality of life in patients with advanced pancreatic cancer who are experiencing significant weight loss.

1Treatment groups

Experimental Treatment

Group I: Ketorolac (open label)Experimental Treatment1 Intervention

Pancreatic patients receiving Ketorolac four times a day for up to five days

Ketorolac Tromethamine is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Toradol for: